Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Medical System Holdings has announced that the Chinese State Food and Drug Administration has approved the renewal of the import drug license of Deanxit.
Subscribe to our email newsletter
This renewal marks the second renewal of the license since Deanxit was first registered with the SFDA in 1999. The license grants H Lundbeck the manufacturer of Deanxit, the right to register, import and sell Deanxit in China, and the new license will be valid until April 2013.
China Medical System (CMS) recently signed a new addendum extending the exclusive agency agreement with H Lundbeck to sell and market Deanxit in China (excluding Hong Kong and Macau) up to the end of 2013.
Lam Kong, CEO of CMS, said: “With continuously strong demand of Deanxit, the exclusive right to market Deanxit in China for the next five years together with the license approved until April 2013, we are confident that sales of Deanxit will continue to perform well in the coming years.”